Olodanrigan sodium  (Synonyms: EMA401 sodium; PD-126055 sodium)

Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons^[1][2][3][4].

"Reverse Transcriptase^[1]
HIV^[1]"

EMA401 sodium（10mg/kg；口服）导致慢性压迫性损伤 (CCI) 后第 14 天大鼠的 θ 功率显着减弱和缩爪潜伏期 (PWL) 增加^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

529.56

C₃₂H₂₈NNaO₅

1316755-17-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383(9929):1637-47.  [Content Brief]

  [2]. Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.  [Content Brief]

  [3]. Suguru Koyama,et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.